TD Cowen raised the firm’s price target on Regeneron to $1,030 from $1,020 and keeps a Buy rating on the shares. The firm updated its model and increased their Eylea HD estimate, and increased Dupi and Libtayo estimates per their IQVIA script analyses.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)
- Regeneron price target raised to $720 from $710 at BofA
- RBC sees buying opportunity following Regeneron’s ‘overdone DOJ downside’
- Regeneron (NASDAQ:REGN) Accused of Manipulating Pricing
- DOJ files false claims act complaint against Regeneron over drug pricing
